CB 1158

Drug Profile

CB 1158

Alternative Names: CB-1158

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Calithera Biosciences; Mars Symbioscience
  • Developer Calithera Biosciences
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Arginase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
  • 15 Sep 2016 Phase-I clinical trials in Cancer (Late-stage disease) in USA (PO) (NCT02903914)
  • 25 Jul 2016 US FDA approves IND application for CB 1158 in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top